,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny-breast07', 'breast', 'daiichisankyous']
today at #asco22: attend our poster presentations on the destiny-breast07 study and the destiny-breast08 study in patients with #her2 expressing #breastcancer. 
Daiichi Sankyo US’s channel featuring our biopharmaceutical news, passion for innovation & compassion for patients.  See our guidelines: https://t.co/4iEAbpw1Wx